LT Pharma
Turnover is estimated at about €980,000, probably between €640,000 and €2.1m.
Balance sheet
balance sheet total €1.5m on 31-12-2025Position in the sector
11.3%
Higher than 20% of the 13,315 companies filing abbreviated accounts in retail trade (NACE 47) in 2025.
0.76
Higher than 15% of the 13,174 companies filing abbreviated accounts in retail trade (NACE 47) in 2025.
10.0%
Higher than 73% of the 13,235 companies filing abbreviated accounts in retail trade (NACE 47) in 2025.
Net result: top quarter · Equity: middle half · Balance sheet total: middle half · Working capital: bottom quarter
Key figures and ratios
per financial year, computed from the annual accounts| Line | Trend | 2025 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 201716 months |
|---|---|---|---|---|---|---|---|---|---|
| 206,697 | 177,598 | 180,905 | 111,798 | 249,557 | 223,294 | - | - | ||
| 153,931 | 131,564 | 133,619 | 80,879 | 181,964 | 411,212 | - | - | ||
| - | 1,232 | 7,400 | 0 | 0 | 29,807 | 800,005 | - | ||
| - | -20,344 | 360,416 | -81,374 | 126,281 | 123,689 | 13,710 | - | ||
| -229,872 | 811,262 | 740,837 | 674,524 | 653,553 | 531,495 | 209,997 | - | ||
| 11.3% | 66.4% | 61.3% | 55.2% | 49.1% | 41.7% | 19.2% | 100.0% | ||
| 0.76 | 13.10 | 11.98 | 9.07 | 5.62 | 5.27 | 3.40 | - | ||
| 7.82 | 0.51 | 0.63 | 0.81 | 1.04 | 1.40 | 4.20 | - | ||
| 88.2% | 11.0% | 12.8% | 8.6% | 22.2% | 65.7% | 91.2% | - | ||
| 10.0% | 7.3% | 7.8% | 4.8% | 10.9% | 27.4% | 17.6% | - | ||
| 29.09 | 18.87 | 18.94 | 10.84 | - | - | - | - |
EBIT margin not included in this filing.
A Belgian filing has no cash-flow statement. Cash flow is therefore an approximation, derived from the income statement. Investment is the acquisitions in the notes and, without them, the balance-sheet move.
Filed annual accounts
as filed with the National Bank, click a year to choose it| Line | Trend | 2025 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 201716 months |
|---|---|---|---|---|---|---|---|---|---|
| Balance sheet: assets | |||||||||
20/58 |
1.5m | 1.7m | 1.6m | 1.6m | 1.6m | 1.5m | 1.1m | 18,600 | |
21/28 |
802,193 | 805,153 | 812,586 | 811,953 | 817,906 | 823,859 | 800,005 | - | |
22/27 |
2,145 | 5,105 | 12,538 | 11,905 | 17,858 | 23,811 | - | - | |
24 |
2,145 | 5,105 | 12,538 | 11,905 | 17,858 | 23,811 | - | - | |
28 |
800,048 | 800,048 | 800,048 | 800,048 | 800,048 | 800,048 | 800,005 | - | |
29/58 |
723,702 | 878,321 | 808,296 | 758,152 | 794,894 | 655,833 | 297,654 | 18,600 | |
40/41 |
506,347 | 297,141 | 197,879 | 499,564 | 444,638 | 420,967 | 175,000 | - | |
40 |
505,425 | 263,500 | 174,800 | 239,200 | 197,500 | 175,000 | - | - | |
41 |
922 | 33,641 | 23,079 | 260,364 | 247,138 | 245,967 | 175,000 | - | |
54/58 |
191,763 | 540,978 | 561,322 | 200,906 | 282,280 | 155,999 | 32,310 | 18,600 | |
490/1 |
25,592 | 40,202 | 49,095 | 57,682 | 67,976 | 78,867 | 90,344 | - | |
| Balance sheet: equity and liabilities | |||||||||
10/49 |
1.5m | 1.7m | 1.6m | 1.6m | 1.6m | 1.5m | 1.1m | 18,600 | |
10/15 |
172,911 | 1.1m | 994,292 | 867,440 | 792,514 | 616,503 | 211,244 | 18,600 | |
10/11 |
18,600 | 18,600 | 18,600 | 18,600 | 18,600 | 18,600 | 18,600 | 18,600 | |
100 |
- | - | - | - | 18,600 | 18,600 | 18,600 | 18,600 | |
13 |
1,860 | 1,860 | 1,860 | 1,860 | 1,860 | 1,860 | 1,860 | - | |
130/1 |
1,860 | 1,860 | 1,860 | 1,860 | 1,860 | - | - | - | |
130 |
- | - | - | - | 1,860 | 1,860 | 1,860 | - | |
1311 |
1,860 | 1,860 | 1,860 | 1,860 | - | - | - | - | |
14 |
152,451 | 1.1m | 973,832 | 846,980 | 772,054 | 596,043 | 190,784 | - | |
17/49 |
1.4m | 566,283 | 626,590 | 702,665 | 820,286 | 863,189 | 886,415 | - | |
17 |
379,410 | 499,224 | 559,131 | 619,037 | 678,945 | 738,851 | 798,758 | - | |
170/4 |
379,410 | 499,224 | 559,131 | 619,037 | 678,945 | 738,851 | 798,758 | - | |
42/48 |
953,574 | 67,059 | 67,459 | 83,628 | 141,341 | 124,338 | 87,657 | - | |
42 |
59,907 | 60,584 | 59,907 | 59,907 | 59,907 | 59,907 | 59,907 | - | |
44 |
- | 2,794 | 2,083 | 2,463 | 3,676 | 2,969 | 7,000 | - | |
440/4 |
- | 2,794 | 2,083 | 2,463 | 3,676 | 2,969 | 7,000 | - | |
45 |
143,945 | 1,424 | 648 | 17,509 | 68,538 | 55,412 | 20,750 | - | |
450/3 |
143,945 | 1,424 | 648 | 17,509 | 68,538 | 52,891 | 20,750 | - | |
454/9 |
- | - | - | - | - | 2,521 | - | - | |
47/48 |
749,722 | 2,257 | 4,821 | 3,749 | 9,220 | 6,050 | - | - | |
492/3 |
20,000 | - | - | - | - | - | - | - | |
| Income statement | |||||||||
9900 |
208,046 | 179,422 | 182,138 | 113,214 | 250,377 | 224,195 | 31,293 | - | |
630 |
1,480 | 8,665 | 6,767 | 5,953 | 5,953 | 5,953 | - | - | |
640/8 |
1,349 | 1,824 | 1,233 | 1,416 | 820 | 901 | 347 | - | |
9901 |
205,217 | 168,933 | 174,138 | 105,845 | 243,604 | 217,341 | 30,946 | - | |
75/76B |
- | - | - | - | - | 252,967 | 175,000 | - | |
75 |
- | - | - | - | - | 252,967 | 175,000 | - | |
65/66B |
7,106 | 9,413 | 9,550 | 10,316 | 11,111 | 11,994 | 8,354 | - | |
65 |
7,106 | 9,413 | 9,550 | 10,316 | 11,111 | 11,994 | 8,354 | - | |
9903 |
198,111 | 159,520 | 164,588 | 95,529 | 232,493 | 458,314 | 197,592 | - | |
67/77 |
45,660 | 36,621 | 37,736 | 20,603 | 56,482 | 53,055 | 4,948 | - | |
9904 |
152,451 | 122,899 | 126,852 | 74,926 | 176,011 | 405,259 | 192,644 | - | |
9905 |
152,451 | 122,899 | 126,852 | 74,926 | 176,011 | 405,259 | 192,644 | - | |
| Appropriation of the result | |||||||||
9906 |
1.0m | 1.1m | 973,832 | 846,980 | 772,054 | 596,043 | 192,644 | - | |
14P |
879,979 | 973,832 | 846,980 | 772,054 | - | - | - | - | |
691/2 |
- | - | - | - | - | - | 1,860 | - | |
6920 |
- | - | - | - | - | - | 1,860 | - | |
694/7 |
879,979 | - | - | - | - | - | - | - | |
694 |
879,979 | - | - | - | - | - | - | - | |
| Document | |||||||||
The full notes are in the accounts filed with the NBB.
Source: Annual accounts 2025 at the NBB, filed on 31-10-2026.
Filings
each dot is a set of accounts, on the day it reached the National BankThe accounts were filed on 31-10-2026. The deadline was 31-07-2026, 7 months after the close on 31-12-2025 (article 3:10 of the Companies and Associations Code). Source: NBB, 2026-00598043.
| Financial year | Type | Filed | Reference | Document |
|---|---|---|---|---|
| 31-12-2025 | abbreviated format | 31-10-2026 | 2026-00598043 | |
| 31-12-2023 | full format | 31-08-2024 | 2024-00458462 | |
| 31-12-2022 | full format | 01-09-2023 | 2023-00440235 | |
| 31-12-2021 | micro format | 31-08-2022 | 2022-20421814 | |
| 31-12-2020 | micro format | 30-08-2021 | 2021-61900049 | |
| 31-12-2019 | micro format | 31-12-2020 | 2020-77900595 | |
| 31-12-2018 | micro format | 31-12-2020 | 2020-77900594 | |
| 31-12-2017 | micro format | 31-08-2018 | 2018-62300185 |
Investments
fixed assets acquired| Item | 2025 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Tangible fixed assets | - | - | €7,400 | - |
| €1,480 | €8,665 | €6,767 | €5,953 |
Source: notes to the 2021 to 2025 annual accounts (statement of fixed assets)
Insights on LT Pharma
The operating result for 2025 is €205,217, against €168,933 in 2023. Comparable figures for the intervening years are unavailable.
Debt's share of the balance-sheet total is 88.7%.